124753-97-5
Chemical Structure
C6 Ceramide
Synonym(s): C6-Cer; N-Hexanoylsphingosine
- CAS No.: 124753-97-5
- Formula:C24H47NO3
- Molecular Weight:397.63
IUPAC Name: N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)hexanamide
InChIKey: NPRJSFWNFTXXQC-QFWQFVLDSA-N
SMILES: CCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
Biological Activity: C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C6 Ceramide | 99.82% | C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ceramide C6-d7 | 99.0% | Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C6 Ceramide-13C2,d2 | C6 Ceramide-13C2,d2 (C6-Cer-13C2,d2) is the deuterium labeled and 13C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C6 Ceramide-d11 | 99.79% | C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2(1):e117. [Content Brief]
- [2]. Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18(1):298. [Content Brief]
- [3]. Mitoma J, et al. Bipotential roles of ceramide in the growth of hippocampal neurons: promotion of cell survival and dendritic outgrowth in dose- and developmental stage-dependent manners. J Neurosci Res. 1998 Mar 15;51(6):712-22. [Content Brief]
- [4]. Flowers M, et al. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat. 2012 Jun;133(2):447-58. [Content Brief]
- [5]. Wilhelm R, et al. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. Cancers (Basel). 2021 Jan 13;13(2):270. [Content Brief]
